Cancer Cell:p62,预测肝癌复发的新型标记物

2016-05-23 QQduhq 译 MedSci原创

圣地亚哥加州大学医学院Michael Karin教授和同事们指出,肝脏肿瘤切除术后若p62水平很高则肿瘤易复发且患者预后不佳,他们还发现,若没有这种蛋白质的存在,则小鼠模型中不会出现肝癌细胞。Karin博士指出,p62可能是一种评估肝癌复发和治疗效果的有效生物标记物。研究结果发表在Cancer Cell。 美国癌症协会指出,只有肝癌和胆管癌患者5年生存率不到17%,由于肝癌患者的生存率低、预后不佳

圣地亚哥加州大学医学院Michael Karin教授和同事们指出,肝脏肿瘤切除术后若p62水平很高则肿瘤易复发且患者预后不佳,他们还发现,若没有这种蛋白质的存在,则小鼠模型中不会出现肝癌细胞。Karin博士指出,p62可能是一种评估肝癌复发和治疗效果的有效生物标记物。研究结果发表在Cancer Cell。 


美国癌症协会指出,只有肝癌和胆管癌患者5年生存率不到17%,由于肝癌患者的生存率低、预后不佳、不宜早期发现,因此探索检测和预防肝癌的新方法是迫切需要的。 

p62的功能是收集细胞代谢废物和携带遭到破坏的蛋白质。它还可以与蛋白质结合,调节细胞生长和存活等过程。研究人员发现,许多肿瘤患者机体的p62水平都会升高,包括肝癌和肝脏疾病癌变前期。 

在新的研究中,研究人员检测了接受治疗并完全消除肿瘤细胞的肿瘤患者,最常见的便是肝癌。依据p62的水平将其分为3类,研究人员发现,121名参与者中有79名患者的p62检测为阳性。研究人员对患者的组织样本进行标记后进行不断随访,以评估参与者的肿瘤有无复发。研究人员发现,p62水平高的参与者更易出现肿瘤复发,且生存率降低。通过从国家检索数据库对450名肝癌患者的基因组数据进行分析,研究人员发现了相同的结果。

在下一阶段的研究中,研究人员希望采用小鼠模型以探究p62是通过何种途径促进癌症复发以帮助肿瘤细胞分裂增殖。他们指出,通过对小鼠模型进行实验,他们发现,肝癌复发和病情恶化必须有p62蛋白的存在。

研究人员希望通过研究可以确定将p62作为新的肝癌标记物并试图从p62入手研制新药以降低肝癌的复发率。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-09-15 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2017-04-03 wjywjy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1780676, encodeId=248f1e80676a6, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 08:31:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808079, encodeId=2b8718080e9d8, content=<a href='/topic/show?id=f2a6812e58e' target=_blank style='color:#2F92EE;'>#肝癌复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81275, encryptionId=f2a6812e58e, topicName=肝癌复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Wed Apr 19 23:31:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959646, encodeId=e5c5195964668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 15 13:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904442, encodeId=292d190444296, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Apr 03 01:31:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138115, encodeId=cf9813811521, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:14:46 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869389, encodeId=f1ff18693892a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 12 01:31:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88222, encodeId=44ca88222d2, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:49:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 mym86538653

    真不错

    0

相关资讯

p62–Keap1–Nrf2–Nqo1 信号通路可能与抗老化有关

韩国媒体报道,韩国成均馆大学医学院分子细胞生物学教室的申在均(音译)教授团队今天表示,透过老鼠实验,发现若缺乏名為p62的基因,则细胞内粒腺体的功能会衰弱,使得快速老化。 研究团队证实,正常老鼠的寿命越老时,p62基因就会急遽减少,p62基因功能越衰弱,就越无法抑制老化。 研究团队表示,p62基因能稳定名為Nrf2的转录因子(transcription factor),使名为Nqo1的抗氧化酵